Pre-Treatment Lymphopenia and NLR May Have Prognostic Value in Turkish High-Grade Glial Tumor Patients
Ali Murat Sedef1, Zuleyha Calikusu2, Aykut Bahceci3, Serkan Gokcay1, Ahmet Taner Sümbül41Department of Medical Oncology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey Department of Medical Oncology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey Department of Medical Oncology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey, 2Department of Medical Oncology, Acıbadem Mehmet Ali Aydinlar University, Adana, Turkey, 3Department of Medical Oncology, Ersin Arslan Training and Research Hospital, Gaziantep, Turkey, 4Department of Medical Oncology, Baskent University Faculy of Medicine, Adana, Turkey
Objectives: We aimed to determine the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocytopenia in Turkish high-grade glial tumor patients. Methods: This study was designed as a hospital-based retrospective observational case series study. A total of 111 patients with recurrent glioblastoma multiforme (GBM) at four different oncology centers in Turkey between 2009 and 2017 have included to our study. Results: All of the patients (n=111) had recurrent disease. Sixty-nine (62.2%) patients died and overall survival (OS) was estimated 28 months. Cutoff NLR value is found as 3.06. The OS of patients who had low NLR was statistically significantly longer than the patients who had high NLR (30 months vs. 23 months, p=0.008). The OS of patients with lymphocytopenia was statistically significantly worse than the other group (24 months vs. 30 months, p=0.04). Progression-free survival was estimated 8 months. Median PFS was statistically better in GBM than the astrocytoma (8 months vs. 4 months, p=0.03). Conclusion: In our study, we showed that high NLR and lymphocytopenia may also have prognostic value in recurrent Turkish high-grade glial tumor patients and the present findings confirm that these markers may be used to predict the mortality risks for these patients. Keywords: NLR, recurrent glial tumor, PLR
Cite This Article
Sedef A, Calikusu Z, Bahceci A, Gokcay S, Sümbül A. Pre-Treatment Lymphopenia and NLR May Have Prognostic Value in Turkish High-Grade Glial Tumor Patients. EJMI. 2021; 5(1): 107-112
Corresponding Author: